Quantcast

Emergent BioSolutions to manufacture another COVID-19 vaccine candidate

Syed Husain, senior vice president and head of contract development and manufacturing at Emergent Biosolutions. (Emergent BioSolutions submitted photo)

Syed Husain, senior vice president and head of contract development and manufacturing at Emergent Biosolutions. (Emergent BioSolutions submitted photo)

A Gaithersburg life sciences company has signed a $135 million deal with another drug company to provide contract development and manufacturing services for its lead COVID-19 vaccine candidate.

Emergent BioSolutions Inc. will provide drug substance manufacturing services supported by investments from Johnson & Johnson beginning in 2020, and will reserve some of its large-scale manufacturing capacity in 2021 for commercial manufacturing of Johnson & Johnson’s vaccine.

To support Johnson & Johnson’s goal of supplying one billion doses of a COVID-19 vaccine, Emergent is negotiating a long-term commercial manufacturing agreement for large-scale drug substance manufacturing anticipated to begin in 2021. Large-scale manufacturing of drug substance for Johnson & Johnson’s vaccine candidate will be done at Emergent’s Baltimore Bayview facility.

Syed T. Husain, senior vice president and contract development and manufacturing business unit head at Emergent, said in a news release that Emergent could make up to 300 million doses to advance the vaccine candidate.

Emergent is also working on COVID-19 vaccine candidates with Vaxart Inc. of South San Francisco, California, as well as with Novavax Inc. of Gaithersburg.

COVID-19 COVERAGE

The Daily Record is providing free access to its coverage of the COVID-19 pandemic.

READ: Maryland's response | Businesses adapt | Law stories
Federal and state aid | Acts of generosity | More COVID-19 stories
CHART: Confirmed cases over time | NEW: LIST: Who's hiring | Map: cases by county
SHARE YOUR PHOTOS: Home offices and work buddies | QUIZ: Test your knowledge

 

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *

*